Contribute Try STAT+ Today

Mark down another failure in the battle against Alzheimer’s disease.

Roche (RHHBY) announced Wednesday morning that it is stopping two clinical trials of a drug it is developing to try to prevent the worsening of Alzheimer’s by targeting protein fragments known as beta-amyloid, which scientists have long believed are a key cause of the brain-destroying disorder. It adds to a heap of failures that includes efforts by just about every large drug company. No medicine has ever been shown to significantly slow Alzheimer’s, and the field has had no successes at all in more than a decade.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • There are differences between the above mentioned antibodies that target different subclasses of amyloid protein. Drug discovery is filled with stories where subtle differences in molecules give remarkable differences in outcome. Agree with the other comment that there is likely a significant immune component to Alzheimer’s- whether triggered by infectious disease, abberant signalling or something else.

  • The anti-amyloid drug candidates don’t seem to be working. It’s time for Big Pharma and government research funders to open their minds and act on the clues suggesting that infectious agents are the triggers of Alzheimer’s.

Comments are closed.